Table 2. Therapeutic efficacy of Zoledronic Acid and Denosumab on CG5 breast cancer xenografts.

Treatment groups#	TWI*	T-C §	Stable disease∞/	ILS&	Lethal
	(%)	(days)	mice treated	(%)	toxicity°
ZOL	44	7	6-Jan	35	0/6
Denosumab	-	0	0/6	8	0/6

^# CG5 tumor bearing-mice were treated starting from day 6 after tumor cells injection, as follows: a) ZOL at 20 μg/mouse i.v. three times a week for three consecutive weeks; b) Denosumab at 10 mg/Kg i.v. two times a week for three for four consecutive weeks. *Tumor weight inhibition was calculated at the nadir of the effect. Statistical significance of differences of tumor weight between each group are as follows: ZOL vs untreated, p = 0.013; ZOL vs Denosumab, p = 0.014. ^§Calculated as the median times for treated (T) and control (C) tumors to reach the same size (1000 mg). ∞Stable disease was defined as the maintenance of the same tumor weight for at least two weeks from the start of treatment. ^&Increase in lifespan. ILS of treated mice was calculated compared their median survival time (MST) with those of untreated mice. The animals were euthanized for ethical reasons when tumors reached a mean of 3.0 g in weight (the time of euthanization was recorded as the time of death). Statistical significance of differences of survival between each group are as follows: ZOL vs untreated, p = 0.002; ZOL vs Denosumab, p = 0.018. °Number of toxic deaths/total number of treated mice.